Gilead Sciences Inc. shares declined in the extended session Tuesday after the biotech topped Wall Street estimates on revenue but not earnings for the third quarter. Gilead shares were last down 1.3% at $73 after hours. The company reported adjusted third-quarter earnings of $2.75 a share on revenue of $7.5 billion. Analysts surveyed by FactSet had forecast adjusted earnings of $2.81 a share on revenue of $7.46 billion. Gilead reiterated its full-year outlook of $29.5 billion to $30.5 billion in revenue. Analysts expect $30.37 billion.
Copyright © 2016 MarketWatch, Inc.